End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 MYR | -.--% | -5.26% | -6.49% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- With a P/E ratio at 10.29 for the current year and 10.59 for next year, earnings multiples are highly attractive compared with competitors.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.49% | 110M | B | ||
+23.03% | 74.04B | C+ | ||
-1.52% | 24.18B | C+ | ||
+3.67% | 8.46B | C | ||
+8.55% | 8.34B | B | ||
-23.71% | 7.64B | B- | ||
+15.20% | 5.33B | B- | ||
-6.90% | 3.92B | B- | ||
+2.68% | 4.12B | B | ||
+5.56% | 3.89B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PHARMA Stock
- Ratings Pharmaniaga